OTCM
SYUP
Market cap15kUSD
Dec 09, Last price
0.00USD
Name
ANBC Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shanghai Yutong Pharma, Inc., a company based in Shanghai, China, specializes in the development, manufacturing, and distribution of both traditional Chinese herbal remedies and cutting-edge biological pharmaceuticals within the People's Republic of China. Their diverse product portfolio addresses a wide range of health concerns. Noteworthy offerings include Qilisheng, crafted to strengthen the immune system and promote overall vitality. Oral solutions such as Qi-ju-di-huang are formulated to support kidney and liver function, while Qing-re-jie-du serves to reduce fever and alleviate heat. Sheng-mai-yin is designed to conserve vital energy and replenish bodily fluids, and Xiao-qing-long provides relief from coughs and difficulty breathing. The company also produces various syrups: Shen-bao targets the treatment of impotence and spermatorrhoea; Ban-xia offers cough suppression; and Gan-mao-zhi-ke combats symptoms of the flu, coughs, and nasal congestion. Further herbal preparations encompass Ban-lan-gen for common cold and influenza relief; Gan-mao-qing-re, which helps to mitigate minor body aches, pains, and fever; Huang-dan-yin-chen, utilized in managing jaundice and infectious hepatitis; and Liu-shen-qu, prescribed for instances of vomiting and dysentery. These pharmaceutical goods are supplied to distributors via a wholesale model.
Key people
Jiangan Lu
President, Director
Dong Wei
Chief Executive Officer, Director
Lishia Lee
Treasurer, Secretary, Director
Wei Zhang
Director
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY |
|---|---|---|
| 2017‑12 | 2016‑12 | |
| Income | ||
Revenues | ||
Cost of revenue | ||
Unusual Expense (Income) | ||
NOPBT | ||
NOPBT Margin | ||
Operating Taxes | ||
Tax Rate | ||
NOPAT | ||
Net income | ||
Dividends | ||
Dividend yield | ||
Proceeds from repurchase of equity | ||
BB yield | ||
| Debt | ||
Debt current | ||
Long-term debt | ||
Deferred revenue | ||
Other long-term liabilities | ||
Net debt | ||
| Cash flow | ||
Cash from operating activities | ||
CAPEX | ||
Cash from investing activities | ||
Cash from financing activities | ||
FCF | ||
| Balance | ||
Cash | ||
Long term investments | ||
Excess cash | ||
Stockholders' equity | ||
Invested Capital | ||
ROIC | ||
ROCE | ||
| EV | ||
Common stock shares outstanding | ||
Price | ||
Market cap | ||
EV | ||
EBITDA | ||
EV/EBITDA | ||
Interest | ||
Interest/NOPBT | ||